![Neil Desai](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Neil Desai
Directeur/Bestuurslid bij
WHITEHAWK THERAPEUTICS, INC.
Vermogen: 9 M $ op 31-05-2026
Profiel
Neil P.
Desai is the founder of Aadi Subsidiary, Inc. since 2011, holding the title of Executive Chairman.
Current job includes Director at Whitehawk Therapeutics, Inc. since 2024.
Former jobs include Director at Mercator MedSystems, Inc., Vice President-Strategic Platforms at Celgene Corp.
from 2010 to 2016, Senior Research Scientist at American Bioscience, Inc. from 1991 to 1994, Senior VP-Global Research & Development at Abraxis BioScience, Inc. from 2008 to 2010, and Vice President-Research & Development at Abraxis BioScience, Inc. from 1999 to 2008.
Education includes graduate and doctorate degrees from The University of Texas at Austin and an undergraduate degree from the Institute of Chemical Technology.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 12-06-2026 | 1.811.241 ( 3,84% ) | 9 M $ | 31-05-2026 |
Actieve functies van Neil Desai
| Bedrijven | Functie | Begin |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-10-2024 |
Aadi Subsidiary, Inc.
 Aadi Subsidiary, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Oprichter | 01-10-2011 |
Eerdere bekende functies van Neil Desai
| Bedrijven | Functie | Einde |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 01-10-2016 |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Manufactures specialty pharmaceutical products | Hoofd Techniek/Wetenschap/O&O | 01-10-2010 |
Abraxis BioScience, Inc. /Old/
 Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Manufactures specialty pharmaceutical products | Hoofd Techniek/Wetenschap/O&O | 01-10-2008 |
Mercator MedSystems, Inc.
 Mercator MedSystems, Inc. Medical SpecialtiesHealth Technology Develops medical injection devices | Directeur/Bestuurslid | - |
American Bioscience, Inc.
 American Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparations | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Neil Desai
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
72
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
American Bioscience, Inc.
American Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparations | Health Technology |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Manufactures specialty pharmaceutical products | Health Technology |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mercator MedSystems, Inc.
Mercator MedSystems, Inc. Medical SpecialtiesHealth Technology Develops medical injection devices | Health Technology |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Manufactures specialty pharmaceutical products | Health Technology |
Institute of Chemical Technology
 Institute of Chemical Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
Aadi Bioscience, Inc.
 Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
